Deep brain stimulation as a new therapeutic approach in therapy-resistant mental disorders: ethical aspects of investigational treatment
- 636 Downloads
Deep brain stimulation (DBS) is an established treatment option for some movement disorders, in particular Parkinson’s disease. Only recently, a number of promising studies with small samples of patients have been published in which impressive therapeutic outcomes achieved by DBS in otherwise treatment-resistant obsessive–compulsive disorder, major depression, and Tourette’s syndrome were reported. It seems probable that the investigational approach to treat mental disorders by DBS will increase substantially. Neurosurgical interventions in psychiatric patients raise ethical considerations not only based on the disreputable experiences of the era of psychosurgery. Therefore, it is necessary to implement transparent and well-defined regulations for the protection of the patients as well as appropriate support for therapeutic research. The current article aims to provide a synopsis of the DBS approach in mental disorders and the hitherto existing criteria for research. It suggests some additional requirements for ethically justifiable therapeutic research employing DBS in psychiatric patients.
KeywordsDeep brain stimulation Neuroethics Mental disorders Major depression Obsessive–compulsive disorder Tourette’s syndrome
Conflicts of interest statement
The authors, Jens Kuhn, W. Gaebel, J. Klosterkötter, and Christiane Woopen, have no financial interests in the subject matter of this article.
- 1.Comité Consultatif National d’Ethique (2002) Functional neurosurgery for severe psychiatric disorders. http://www.ccne-ethique.fr/docs/en/avis071.pdf. Accessed 20 May 2009
- 3.German Parkinson Study Group (GPS) (2009) Controlled trial of deep brain stimulation in early patients with Parkinson’s disease. http://clinicaltrials.gov/ct2/show/NCT00354133. Accessed 20 May 2009
- 4.Greenberg BD, Gabriels LA, Malone DA Jr, Rezai AR, Friehs GM, Okun MS, Shapira NA, Foote KD, Cosyns PR, Kubu CS, Malloy PF, Salloway SP, Giftakis JE, Rise MT, Machado AG, Baker KB, Stypulkowski PH, Goodman WK, Rasmussen SA, Nuttin BJ (2008) Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive–compulsive disorder: worldwide experience. Mol Psychiatry [Epub ahead of print]Google Scholar
- 5.Huff W, Lenartz D, Schormann M, et al. (2009) Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment resistant obsessive compulsive disorder—outcomes after one-year stimulation. Clin Neurol Neurosurg (in press)Google Scholar
- 11.Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group (2008) Subthalamic nucleus stimulation in severe obsessive–compulsive disorder. N Engl J Med 359:2121–2134Google Scholar
- 16.Merkel R, Boer G, Fegert J, Galert T, Hartmann D, Nuttin B, Rosahl S (2007) Intervening in the brain: changing psyche and society. Springer, HeidelbergGoogle Scholar
- 17.Miller FG, Fins JJ (2006) Protecting human subjects in brain research: a pragmatic perspective. In: Illes J (ed) Neuroethics: defining the issues in theory, practice. Oxford University Press, Oxford, pp 123–140Google Scholar
- 19.Moniz E (1937) Prefrontal leucotomy in the treatment of mental disorders. Am J Psychiatry 93:1379–1385Google Scholar
- 29.U.S. Food and Drug Administration (2009) New humanitarian device approval. www.fda.gov/cdrh/mda/docs/H050003.html. Accessed 26 May 2009